Back Back
ProCE Banner Activity

CME

The Role of Bridging Therapeutic Strategies for Patients With Multiple Myeloma Receiving CAR T-Cell Therapy

Text Module

Thomas G. Martin, MD, provides expert guidance on bridging and other treatment strategies for the real-world implementation of CAR T-cell therapy for patients with relapsed/refractory multiple myeloma, including up-to-date clinical trial data and future directions affecting the placement of CAR T-cell therapy in the treatment landscape.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit™

Released: July 17, 2023

Expiration: July 16, 2024

No longer available for credit.
Begin Activity

Share

Faculty

Thomas G. Martin

Thomas G. Martin, MD

Clinical Professor of Medicine
Associate Chief, Division of Hematology/Oncology
Co-Lead, Cancer Immunology and Immunotherapy Program
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb

Target Audience

This educational program is intended for hematologists, oncologists, and other healthcare professionals who care for patients with multiple myeloma receiving CAR T-cell therapy.

Program Learning Goal

The goal of this activity is to educate hematologists, oncologists, and other healthcare professionals involved in the care of patients with multiple myeloma receiving CAR T-cell therapy.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate the challenges of access to and manufacturing of CAR T-cell therapy and role of bridging therapeutic strategies in patients with multiple myeloma 

  • Identify patients with multiple myeloma who are likely to benefit from bridging therapy prior to CAR T-cell treatment

  • Select optimal regimens, duration, and timing for bridging therapy for patients with multiple myeloma receiving CAR T-cell therapy based on expert guidance and available clinical evidence

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Thomas G. Martin, MD

Clinical Professor of Medicine
Associate Chief, Division of Hematology/Oncology
Co-Lead, Cancer Immunology and Immunotherapy Program
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Thomas G. Martin, MD: researcher (paid to institution): Amgen, Janssen, Sanofi; consultant: GlaxoSmithKline, Legend Biotech.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from July 17, 2023, through July 16, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

The program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint Accreditation

 

 

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Educations (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.